当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:242.88亿  总市值:288.72亿
流通股本:6.30亿   总股本:7.49亿

现金流量表

报告期2025-12-312025-09-302025-06-302025-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,772,381,774.151,273,147,554.37835,220,095.37393,009,966.08
  收到的税费返还7,291,392.166,368,337.793,521,200.65806,423.22
  收到其他与经营活动有关的现金52,454,155.5443,956,095.0337,237,275.8435,988,568.22
  经营活动现金流入小计1,832,127,321.851,323,471,987.19875,978,571.86429,804,957.52
  购买商品、接受劳务支付的现金567,303,820.73401,692,918.2255,061,869.13109,851,243.37
  支付给职工以及为职工支付的现金658,177,529.56528,437,549.04362,670,351.19202,650,410.26
  支付的各项税费63,156,061.1752,826,422.9944,636,272.5826,290,323.55
  支付其他与经营活动有关的现金98,923,188.2674,123,947.6450,837,084.1325,863,779.18
  经营活动现金流出小计1,387,560,599.721,057,080,837.87713,205,577.03364,655,756.36
  经营活动产生的现金流量净额444,566,722.13266,391,149.32162,772,994.8365,149,201.16
二、投资活动产生的现金流量:
  收回投资收到的现金2,276,223,325.911,903,795,691.671,017,911,291.67611,998,000
  取得投资收益收到的现金75,133,433.2462,042,621.8520,527,967.295,612,767.24
  处置固定资产、无形资产和其他长期资产收回的现金净额1,361,360.161,145,178.4636,965.242,945.24
  收到的其他与投资活动有关的现金17,793,632.08---
  投资活动现金流入小计2,370,511,751.391,966,983,491.981,038,476,224.2617,613,712.48
  购建固定资产、无形资产和其他长期资产支付的现金143,602,144.53121,121,329.5689,303,769.2446,814,440.04
  投资支付的现金2,646,102,552.692,110,584,774.911,384,184,774.91904,759,050.91
  投资活动现金流出小计2,789,704,697.222,231,706,104.471,473,488,544.15951,573,490.95
  投资活动产生的现金流量净额-419,192,945.83-264,722,612.49-435,012,319.95-333,959,778.47
三、筹资活动产生的现金流量:
  分配股利、利润或偿付利息支付的现金22,385,22922,385,229--
  支付其他与筹资活动有关的现金44,598,826.3136,603,316.9128,180,254.5718,665,128.1
  筹资活动现金流出小计66,984,055.3158,988,545.9128,180,254.5718,665,128.1
  筹资活动产生的现金流量净额-66,984,055.31-58,988,545.91-28,180,254.57-18,665,128.1
四、汇率变动对现金及现金等价物的影响-11,738,509.02-5,822,610.67-2,551,375.3-1,154,223.86
五、现金及现金等价物净增加额-53,348,788.03-63,142,619.75-302,970,954.99-288,629,929.27
  加:期初现金及现金等价物余额965,203,128.59965,203,128.59965,203,128.59965,201,085.72
  期末现金及现金等价物余额911,854,340.56902,060,508.84662,232,173.6676,571,156.45
补充资料:
  净利润297,842,526.3-60,932,376.38-
  资产减值准备156,760,636.98-66,010,456.08-
  固定资产和投资性房地产折旧94,903,390.14-45,228,713.36-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧94,903,390.14-45,228,713.36-
  无形资产摊销17,422,245.12-8,041,663.14-
  长期待摊费用摊销19,269,954.04-10,656,937.26-
  递延收益摊销4,818,186.92-8,924,489.34-
  处置固定资产、无形资产和其他长期资产的损失-413,517.67-44,025.87-
  固定资产报废损失461,919.3--152,132.42-
  公允价值变动损失-447,560,334.54--107,019,073.28-
  财务费用-53,994,754.17--30,344,182.68-
  投资损失-18,013,906.02--13,135,262.03-
  递延所得税119,241.75-1,267,989.53-
  其中:递延所得税资产减少-6,320,664.55-3,917,588.08-
    递延所得税负债增加6,439,906.3--2,649,598.55-
  存货的减少214,517,124.57--24,389,766.63-
  经营性应收项目的减少62,295,986.6-84,804,281.28-
  经营性应付项目的增加68,228,112.06-43,202,349.46-
  现金的期末余额911,854,340.56-662,232,173.6-
  减:现金的期初余额965,203,128.59-965,203,128.59-
  现金及现金等价物的净增加额-53,348,788.03--302,970,954.99-
公告日期2026-03-312025-10-312025-08-272025-04-29
审计意见(境内)标准无保留意见
TOP↑